Literature DB >> 11355943

Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.

F G Perabo1, S Kamp, D Schmidt, H Lindner, G Steiner, R H Mattes, A Wirger, K Pegelow, P Albers, E C Kohn, A von Ruecker, S C Mueller.   

Abstract

Mechanisms of resistance against Fas-mediated cell killing have been reported in different malignancies. However, the biological response of immune escape mechanisms might depend on malignant transformation of cancer cells. In this study we investigated different mechanisms of immune escape in 2 well-differentiated low-grade (RT4 and RT112) and 2 poorly differentiated high-grade (T24 and TCCSUP) bladder cancer cell lines. Fas, the receptor of Fas-ligand, is expressed and shedded by human transitional bladder carcinoma cell lines RT4, RT112, T24 and TCCSUP. Cytotoxicity and apoptosis assays demonstrate that in spite of the Fas expression, poorly differentiated T24 and TCCSUP cells are insensitive towards either recombinant Fas-ligand or agonistic apoptosis-inducing monoclonal antibody against Fas. In poorly differentiated T24 and TCCSUP cell lines we were able to detect marked Fas-ligand protein by flow cytometry and Western blot analysis. In grade 1 RT4 and RT112 cells only minor expression of Fas-ligand possibly because of proteinase action. Fas-ligand mRNA translation or post-translational processing seems to be regulated differentially in the cancer cell lines depending on malignant transformation. In co-culture experiments we show that poorly differentiated cells can induce apoptosis and cell death in Jurkat cells and activated peripheral blood mononuclear cells. This in vitro study suggests that bladder cancer cells can take advantage of different mechanisms of immune evasion and become more competent in avoiding immune surveillance during transformation to higher-grade malignant disease. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11355943      PMCID: PMC2363638          DOI: 10.1054/bjoc.2001.1808

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  51 in total

1.  CD95 ligand expression in dedifferentiated breast cancer.

Authors:  M Müschen; C Moers; U Warskulat; D Niederacher; B Betz; J Even; A Lim; R Josien; M W Beckmann; D Häussinger
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

2.  Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.

Authors:  B R Gastman; Y Atarshi; T E Reichert; T Saito; L Balkir; H Rabinowich; T L Whiteside
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

3.  Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

Authors:  C Gratas; Y Tohma; E G Van Meir; M Klein; M Tenan; N Ishii; O Tachibana; P Kleihues; H Ohgaki
Journal:  Brain Pathol       Date:  1997-07       Impact factor: 6.508

4.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

5.  Human lung carcinomas express Fas ligand.

Authors:  G A Niehans; T Brunner; S P Frizelle; J C Liston; C T Salerno; D J Knapp; D R Green; R A Kratzke
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

6.  Transitional cell carcinoma expresses high levels of Fas ligand in vivo.

Authors:  S H Lee; J Y Lee; W S Park; S Y Kim; J J Jang; N J Yoo
Journal:  BJU Int       Date:  1999-04       Impact factor: 5.588

7.  TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis.

Authors:  Y Chicheportiche; P R Bourdon; H Xu; Y M Hsu; H Scott; C Hession; I Garcia; J L Browning
Journal:  J Biol Chem       Date:  1997-12-19       Impact factor: 5.157

8.  Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis.

Authors:  U von Reyher; J Sträter; W Kittstein; M Gschwendt; P H Krammer; P Möller
Journal:  Cancer Res       Date:  1998-02-01       Impact factor: 12.701

9.  Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells.

Authors:  A M Bamberger; H M Schulte; I Thuneke; I Erdmann; C M Bamberger; S L ASA
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

10.  Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing.

Authors:  T Suda; H Hashimoto; M Tanaka; T Ochi; S Nagata
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

View more
  8 in total

Review 1.  Immunological basis in the pathogenesis and treatment of bladder cancer.

Authors:  David B Thompson; Larry E Siref; Michael P Feloney; Ralph J Hauke; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2014-11-13       Impact factor: 4.473

2.  Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.

Authors:  Qiang Zhu; Ji-Yong Liu; Hong-Wei Xu; Chong-Mei Yang; An-Zhong Zhang; Yi Cui; Hong-Bo Wang
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

Review 3.  Expression profiling for bladder cancer: strategies to uncover prognostic factors.

Authors:  Georg Bartsch; Anirban P Mitra; Richard J Cote
Journal:  Expert Rev Anticancer Ther       Date:  2010-12       Impact factor: 4.512

4.  Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression.

Authors:  Dominique Chopin; Reza Barei-Moniri; Pascale Maillé; Marie-Aude Le Frère-Belda; Béatrice Muscatelli-Groux; Nicolò Merendino; Laure Lecerf; Antonella Stoppacciaro; Francesca Velotti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 5.  The immunoregulatory mechanisms of carcinoma for its survival and development.

Authors:  Caigan Du; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2011-01-21

6.  Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes.

Authors:  Mengsen Li; Xinhua Liu; Sheng Zhou; Pingfeng Li; Gang Li
Journal:  BMC Cancer       Date:  2005-08-05       Impact factor: 4.430

7.  Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.

Authors:  Judith Knievel; Wolfgang A Schulz; Annemarie Greife; Christiane Hader; Tobias Lübke; Ingo Schmitz; Peter Albers; Günter Niegisch
Journal:  Int J Mol Sci       Date:  2014-11-07       Impact factor: 5.923

8.  Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.

Authors:  Tim Mandelkow; Niclas C Blessin; Eva Lueerss; Laura Pott; Ronald Simon; Wenchao Li; Björn Wellge; Nicolaus F Debatin; Doris Höflmayer; Jakob R Izbicki; Franziska Büscheck; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Florian Lutz; Eike Burandt; Stefan Steurer; Guido Sauter; Maria Christina Tsourlakis; Waldemar Wilczak; Andrea Hinsch; Sarah Minner
Journal:  Dis Markers       Date:  2019-05-02       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.